# A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

> **NCT02661815** · PHASE1 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 6 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Ricolinostat
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02661815
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-15
- **Primary completion:** 2017-06-28
- **Final completion:** 2017-07-28
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Company decided not to move forward with further accrual.
- **Last updated:** 2019-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661815, "A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02661815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*